Rustem Gafanov

7.1k total citations · 2 hit papers
49 papers, 1.4k citations indexed

About

Rustem Gafanov is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Rustem Gafanov has authored 49 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Pulmonary and Respiratory Medicine, 30 papers in Oncology and 15 papers in Molecular Biology. Recurrent topics in Rustem Gafanov's work include Renal cell carcinoma treatment (28 papers), Cancer Immunotherapy and Biomarkers (23 papers) and Prostate Cancer Treatment and Research (15 papers). Rustem Gafanov is often cited by papers focused on Renal cell carcinoma treatment (28 papers), Cancer Immunotherapy and Biomarkers (23 papers) and Prostate Cancer Treatment and Research (15 papers). Rustem Gafanov collaborates with scholars based in Russia, United States and Canada. Rustem Gafanov's co-authors include Frédéric Pouliot, Michael B. Atkins, Dmitry Nosov, Elizabeth R. Plimack, Bohuslav Melichar, Sérgio Jobim Azevedo, Denis Soulières, Brian I. Rini, Ray McDermott and V.P. Stus and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Rustem Gafanov

42 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

2020 498 citations Thomas Powles, Elizabeth R. Plimack et al. profile →
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma

2021 183 citations David F. McDermott, Jae‐Lyun Lee et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rustem Gafanov Russia	17	1.2k	846	570	438	300	49	1.4k
Dmitry Nosov Russia	12	941 0.8×	542 0.6×	533 0.9×	410 0.9×	201 0.7×	40	1.2k
Ronan Flippot France	18	826 0.7×	630 0.7×	567 1.0×	412 0.9×	196 0.7×	80	1.3k
Meghara Walsh United States	11	833 0.7×	499 0.6×	515 0.9×	379 0.9×	290 1.0×	20	1.1k
Lisa Pickering United Kingdom	17	705 0.6×	378 0.4×	603 1.1×	384 0.9×	234 0.8×	74	1.2k
Caroline E. McCoach United States	18	1.0k 0.9×	757 0.9×	413 0.7×	383 0.9×	290 1.0×	56	1.5k
Dingwei Ye China	17	621 0.5×	417 0.5×	502 0.9×	286 0.7×	303 1.0×	88	1.2k
Jakub Żołnierek Poland	11	788 0.7×	442 0.5×	617 1.1×	452 1.0×	98 0.3×	23	1.1k
Andrea Marchetti Italy	13	629 0.5×	564 0.7×	369 0.6×	276 0.6×	202 0.7×	48	1.2k
Joshua Zhang United States	15	668 0.6×	488 0.6×	375 0.7×	279 0.6×	179 0.6×	56	894
Vesna Šneller United States	7	582 0.5×	360 0.4×	584 1.0×	361 0.8×	102 0.3×	12	995

Countries citing papers authored by Rustem Gafanov

Since Specialization

Citations

This map shows the geographic impact of Rustem Gafanov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rustem Gafanov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rustem Gafanov more than expected).

Fields of papers citing papers by Rustem Gafanov

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rustem Gafanov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rustem Gafanov. The network helps show where Rustem Gafanov may publish in the future.

Co-authorship network of co-authors of Rustem Gafanov

This figure shows the co-authorship network connecting the top 25 collaborators of Rustem Gafanov. A scholar is included among the top collaborators of Rustem Gafanov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rustem Gafanov. Rustem Gafanov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rini, Brian I., Elizabeth R. Plimack, V.P. Stus, et al.. (2024). Biomarker analysis of the phase 3 KEYNOTE-426 study of pembrolizumab (P) plus axitinib (A) versus sunitinib (S) for advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology. 42(16_suppl). 4505–4505. 8 indexed citations

Gafanov, Rustem, et al.. (2024). Metastatic castration-resistant prostate cancer and immune checkpoint inhibitors. Cancer Urology. 20(1). 153–163.

Petrylak, Daniel P., Raffaele Ratta, Nobuaki Matsubara, et al.. (2023). Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 41(6_suppl). 129–129. 1 indexed citations

Petrylak, Daniel P., Raffaele Ratta, Nobuaki Matsubara, et al.. (2023). Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study.. Journal of Clinical Oncology. 41(6_suppl). 19–19. 24 indexed citations

Alekseev, B. Yа., et al.. (2022). Epidemiology and natural history of non-metastatic castration-resistant prostate cancer in Russia. Cancer Urology. 18(2). 111–122.

Powles, Thomas, Elizabeth R. Plimack, V.P. Stus, et al.. (2022). Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426.. Journal of Clinical Oncology. 40(16_suppl). 4513–4513. 4 indexed citations

McDermott, David F., Jae‐Lyun Lee, Marek Ziobro, et al.. (2021). Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology. 39(9). 1029–1039. 183 indexed citations breakdown →

Petrylak, Daniel P., Raffaele Ratta, Rustem Gafanov, et al.. (2021). KEYNOTE-921: Phase III Study of Pembrolizumab Plus Docetaxel for Metastatic Castration-Resistant Prostate Cancer. Future Oncology. 17(25). 3291–3299. 32 indexed citations

McDermott, David F., Jae‐Lyun Lee, Georg A. Bjarnason, et al.. (2021). Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology. 39(9). 1020–1028. 90 indexed citations

10.

Smith, Matthew R., Shahneen Sandhu, Daniel J. George, et al.. (2021). 582P Health-related quality of life (HRQoL) at final analysis of the GALAHAD study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA repair defects (DRD). Annals of Oncology. 32. S632–S633. 1 indexed citations

11.

Gafanov, Rustem, et al.. (2020). Combination of pembrolizumab and axitinib: a new gold standard in the first-line therapy for metastatic clear-cell renal-cell carcinoma?. SHILAP Revista de lepidopterología. 16(3). 29–37.

12.

Alekseev, B. Yа., et al.. (2020). An interim analysis of non-interventional study of the epidemiology and natural history of non-metastatic castration-resistant prostate cancer in Russia. SHILAP Revista de lepidopterología. 16(3). 90–101. 1 indexed citations

13.

Tsimafeyeu, Ilya, et al.. (2020). Nivolumab in patients with metastatic renal cell carcinoma and chronic hepatitis C virus infection. Cancer Immunology Immunotherapy. 69(6). 983–988. 10 indexed citations

14.

Bono, Johann S. de, Sergio Bracarda, Cora N. Sternberg, et al.. (2020). LBA4 IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 31. S1153–S1154. 22 indexed citations

15.

Gafanov, Rustem, et al.. (2018). Metastatic hormone-sensitive prostate cancer: Practical guidelines and optimization of therapy selection. Cancer Urology. 14(4). 139–149. 1 indexed citations

16.

Gafanov, Rustem, et al.. (2018). Metastatic castration-resistant prostate cancer: a current view on drug therapy and alternative tumor cell regulation. Cancer Urology. 14(1). 107–116. 3 indexed citations

17.

Powles, Thomas, Jürgen E. Gschwend, Yohann Loriot, et al.. (2017). Pembrolizumab ± chemotherapy versus chemotherapy in advanced urothelial cancer: Phase 3 KEYNOTE-361 trial. Annals of Oncology. 28. v326–v326. 2 indexed citations

18.

Gafanov, Rustem. (2016). Hormonal therapy and chemotherapy in patients with hormone-sensitive prostate cancer. Cancer Urology. 12(1). 63–68. 3 indexed citations

19.

Gafanov, Rustem, et al.. (2016). Current view: leiomyosarcoma of the veins of the retroperitoneum. Case histories review. Cancer Urology. 12(2). 92–96. 1 indexed citations

20.

Alekseev, B. Yа., И. Г. Русаков, М. И. Волкова, et al.. (2016). Resolution on the results of the Meeting of Experts on the treatment of castrate-resistant prostate cancer. Cancer Urology. 12(3). 109–110. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact